



Docket No. 1645/2900

1645  
JUL 30 2003  
RECEIVED  
TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re patent application of

Applicant: Jerzy A. Georgiades  
Serial No.: 09/980347  
Filed: 22 October 2002  
For: PEPTIDES

Art Unit: 1645  
Examiner:

#13  
P.J.C  
8/19/03

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

1. Pursuant to 37 C.F.R. 1.97 and 1.98, and in compliance with 37 C.F.R. 1.56, the Office's attention is directed to the patents, publications and other information listed on the attached PTO-SB-08A. A copy of each listed document is enclosed except for: (a) pending applications or (b) those previously cited or submitted to the Office in the following application(s) upon which this application relies for an earlier filing date under 35 U.S.C. 120:

Serial No.:  
Filing Date:

Regarding any document, publication or other information for which a date is not given on the attached PTO-1449, Applicant(s) believe(s) the same may qualify as "prior" art to this application and should be treated accordingly, although Applicant(s) reserve(s) the right to contest the prior art status of any document, publication or information, should issue arise.

2. Regarding each listed document that is not in the English language, an English-language translation accompanies this Statement as indicated on the attached PTO-SB-08 or a concise explanation of the relevance of the document is set forth in the following document(s):

- (a)  Copy of each English language version of a search report indicating the degree of relevance found by the foreign office of each document being submitted from the search report.
- (b)  Attachment entitled "Concise Explanation of Relevance of Non-English Language Documents".

3. Pursuant to 37 C.F.R. 1.97(b) this Statement is being filed (one must be checked):

(a)  Within 3 months of the filing date or date of entry into the National Stage.

(b)  Before the mailing date of a first Office Action on the merits. If this Statement is not filed before the mailing date of a first Office Action on the merits, the required certification is given below or, in the absence thereof, the Office is authorized to charge the required fee set forth in 37 C.F.R. 1.17(p) to Deposit Account No. 180160 consideration of this Statement.

(c)  After the period set forth in 37 C.F.R. 1.97(b) but before the mailing date of either a final action or a notice of allowance.

(1)  The required certification is given below, or

(2)  Enclosed is a check covering the fee set forth in 37 C.F.R. 1.17(p) for consideration of this Statement, or

(3)  Charge the fee set forth in 37 C.F.R. 1.17(p) to Deposit Account No. 180160.

(d)  After the mailing date of either a final action or a notice of allowance, but before payment of the issue fee. Petition hereby is made for consideration of this Statement and the required certification is indicated below.

(1)  Enclosed is a check covering the fee set forth in 37 C.F.R. 1.17(i)(1), or

(2)  Charge the fee set forth in 37 C.F.R. 1.17(i)(1) to Deposit Account No. 180160.

4. Certification (if applicable)

(a)  The undersigned hereby certifies that each item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of this Statement.

(b)  The undersigned hereby certifies that no item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the undersigned's knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than 3 months prior to the filing of this Statement.

5. The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 180160.

Respectfully Submitted,

**RANKIN, HILL, PORTER & CLARK LLP**

By \_\_\_\_\_

  
Kenneth A. Clark  
Reg. No. 32,119

925 Euclid Avenue  
Suite 700  
Cleveland, Ohio 44115-1405  
216/566-9700

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence (along with any paper referenced as being attached or enclosed) is being deposited on the below date with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: 25 July 2003

Kathryn A. Kelley



PTO/SB/08A (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## Shee

1 of

4

***Complete if Known***

<b>Application Number</b>	09/980347
<b>Filing Date</b>	22 October 2002
<b>First Named Inventor</b>	Jerzy A. Georgiades
<b>Art Unit</b>	1645
<b>Examiner Name</b>	

Attorney Docket Number AAT-12792

## U.S. PATENT DOCUMENTS

TECH CENTER 1600/2900

JUL 30 2003

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)			
		EP 0583074	B1	09-22-1999	Calpis Co., Ltd.
		PCT/EP96/05846		07-10-1997	Midia Limited
		PCT/GB97/02721		04-09-1998	Ludwick Hirschfeld
		PCT/GB00/02128		12-14-2000	Regen Therapeutics
		HU 208089	B	05-28-1991	Biotech Pharma

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See *Kinds Codes of USPTO Patent Documents* at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

### Complete if Known

Application Number	09/980347
Filing Date	22 October 2002
First Named Inventor	Jerzy A. Georgiades
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	AAT-12792

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
		PCT International Search Report dated March 4, 1998 for PCT/GB97/02721, four pages
		Search Report for HU P9904368 dated June 5, 2000, four pages
		FEBS Letters, Volume 49, Number 2, December 1974, Janusz et al. "Isolation And Characterization Of A Proline-Rich Polypeptide From Ovine Colostrum," pp 276-279
		Janusz et al. "Proline-Rich Polypeptide (PRP) - an Immunomodulatory Peptide from Ovine Colostrum, 1993, Archivum Immunologiae et Therapiae Experimentalis 1993
		Janusz et al., "Chemical and physical characterization of a proline-rich polypeptide from sheep colostrum," 1981 The Biochemical Journal, Vol. 199, pp 9-15
		Zimecki et al., "Effect Of A Proline-Rich Polypeptide (PRP) On The Development Of Hemolytic Anemia...," Archivum Immunologiae et Therapiae Experimentalis 1991
		Unlisted Drugs, March 1989, Vol. 41, No. 3, Page 52
		Provot et al., "Complete sequence of the ovine $\beta$ -casein-encoding gene and interspecies comparison," Gene, 154 (1995) pp 259-263
		Carles et al., "A new strategy for primary structure determination of proteins: application to bovine $\beta$ -casein," 1988 Fed. of European Biochemical Soc., pp 265-272
		Greenberg et al., "Human $\beta$ -Casein," The Journal of Biological Chemistry, Vol. 259, No. 8, Issue of April 25, pp 5132-5138, 1984
		Szewczuk et al., "Proline Rich Polypeptide (PRP) Fragments And Their Immunoregulatory Properties," 20th European Peptide Symposium, Sept. 4-9, 1988

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUL 30 2003

RECEIVED  
TECH CENTER 1600/2000



PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

### Complete if Known

Application Number	09/980347
Filing Date	22 October 2002
First Named Inventor	Jerzy A. Georgiades
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	AAT-12792

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TECH CENTER 1600/2300
		<p>Otani et al., "The common antigenic site of bovine and human <math>\beta</math>-caseins," XP-000952715, pp 705-707, Milchwissenschaft 43 (11) 1988</p> <p>Brezden et al., "FMRFamide-Activated CA2+ Channels in Lymnaea Heart Cells Are Modulated by..." XP-002155471, pp 1818-1826</p> <p>Slootstra et al., "Structural aspects of antibody-antigen interaction revealed through small random peptide libraries," Molecular Diversity, 1 (1995) XP-002051008, pp 87-96</p> <p>Paucha et al., "Immunoprecipitation of Some Forms of Simian Virus 40 Large-T Antigen by Antibodies to..." Journal of Virology, Sept. 1984, Vol. 51, No. 3, pp 670-681</p> <p>Kim et al., "A novel member of the RING finger family, KRIP-1, associates with the..." Genetics, Vol. 93, pp. 15299-15304, December 1996, Proc. Natl. Acad. Sci. USA</p> <p>English translation of Hungarian Patent No. HU 208,089B filed April 18, 1989 and published May 28, 1991</p>	

Examiner  
Signature

Date  
Considered

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

JUL 30 2003

RECEIVED



JUL 28 2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

### Complete if Known

Application Number	09/980347
Filing Date	22 October 2002
First Named Inventor	Jerzy A. Georgiades
Group Art Unit	1645
Examiner Name	
Attorney Docket Number	AAT-12792

JUL 30 2003

RECEIVED

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2 1600/2000
		Abstract and bibliographic data for JP 19920315515, XP-002155476	
		Abstract and bibliographic data for JP 19930043047, XP-002155477	
		Abstract and bibliographic data for JP 19950094516, XP-002155478	
		Abstract and bibliographic data for JP 19880211696, XP-002155479	
		Gidrol et al., "Annexin-like protein from <i>Arabidopsis thaliana</i> rescues..." <i>Plant Biology</i> , Proc. Natl. Acad. Sci., Vol. 93, October 1996, pp. 11268-11273, XP-002155474	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.